A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas

3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine(®)) is a novel small molecule inhibitor of ribonucleotide reductase (RR) with clinical signs of activity in pancreatic cancer. Therefore, the Phase 2 Consortium (P2C) initiated a trial (two single stage studies with planned interim a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Attia, Steven, Kolesar, Jill, Mahoney, Michelle R., Pitot, Henry C., Laheru, Daniel, Heun, James, Huang, Wei, Eickhoff, Jens, Erlichman, Charles, Holen, Kyle D.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4461052/
https://ncbi.nlm.nih.gov/pubmed/18278438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-008-9123-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires